Stay informed with the latest litigation news. Explore now

IP Verse

Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6) - EP2567709B1

EP2567709

NOVARTIS
Application Number
EP12188230A
Filing Date
Oct 31, 2008
Status
Granted And Under Opposition
Nov 24, 2017
Grant Date
Dec 27, 2017
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3143995B2
EP4321157B1
EP3487881B1

Bibliography

The patent EP2567709B1 was granted to Novartis on Dec 27, 2017 following the initial filing on Oct 31, 2008 under the application number EP12188230A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

MERCK PATENTSep 27, 2018ADMISSIBLE
BOEHRINGER INGELHEIM RCV BOEHRINGER INGELHEIMSep 25, 2018WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents